Medallion Wealth Advisors’s Myriad Genetics MYGN Stock Holding History

Medallion Wealth Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-300	Closed	-$1.84K	–	1141
2025 Q4	$1.84K	Hold	300	–	–	﹤0.01%	1000
2025 Q3	$2.17K	Hold	300	–	–	﹤0.01%	968
2025 Q2	$1.59K	Hold	300	–	–	﹤0.01%	982
2025 Q1	$2.66K	Hold	300	–	–	﹤0.01%	884
2024 Q4	$2.66K	Buy	+300	New	+$5.54K	﹤0.01%	824

Other funds holding MYGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Medallion Wealth Advisors's MYGN Position: Q1 2026 in Review

Medallion Wealth Advisors sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 300 shares — an estimated $1.84K sold.

Medallion Wealth Advisors first reported a position in MYGN in Q4 2024 and held it in 5 quarters. The position peaked at $2.66K in Q1 2025. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Medallion Wealth Advisors reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
Medallion Wealth Advisors sold 300 Myriad Genetics shares in Q1 2026, an estimated $1.84K.
Medallion Wealth Advisors first reported a position in Myriad Genetics in Q4 2024 and held it in 5 quarters.
Medallion Wealth Advisors's Myriad Genetics position peaked at $2.66K in Q1 2025.
202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Medallion Wealth Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.